Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | SCD | O00767 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22174136 | 0.83 | NAAA (0.51) | NAAAMMP3SCDEPHX2KMT2A | |
| SCHEMBL15996197 | 0.82 | CA1 (0.46) | MMP3EPHX2KMT2AMEN1RAB9A | |
| SCHEMBL518106 | 0.82 | NAMPT (0.56) | NAAAMMP3EPHX2 | |
| SCHEMBL17729479 | 0.81 | EPHX2 (0.46) | SCDEPHX2KMT2AMEN1RIPK1 | |
| SCHEMBL4186680 | 0.81 | POLB (0.41) | MMP3SCDEPHX2LMNASMN1; SMN2 | |
| SCHEMBL16422271 | 0.81 | LIPG (0.50) | EPHX2RIPK1 | |
| SCHEMBL18318961 | 0.81 | FASN (0.47) | SCDACACB | |
| SCHEMBL14992804 | 0.78 | EPHX2 (0.46) | SCDEPHX2RIPK1USP30SCD5 | |
| SCHEMBL21825158 | 0.78 | HRH3 (0.51) | NAAAEPHX2USP30 | |
| SCHEMBL31347793 | 0.77 | KDM4E (0.56) | NAAAMMP3EPHX2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383871-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2019-08-20 | — | — | US | claimed |
| US-20170196864-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | claimed |
| US-9475800-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2016-10-25 | — | — | US | claimed |
| US-20150183769-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2015-07-02 | — | — | US | claimed |
| US-9006269-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2015-04-14 | — | — | US | claimed |
| US-20130331371-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2013-12-12 | — | — | US | claimed |
| US-8450346-B2 | Azetidine derivatives as FAAH inhibitors | VERNALIS (R&D) LTD. (GB) | 2013-05-28 | — | — | US | claimed |
| US-20240180905-A1 | USES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN TREATMENT OF TRAUMA RELATED PSYCHIATRIC DISORDERS | NEURITEK LTD. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4243811-A1 | USES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN TREATMENT OF TRAUMA RELATED PSYCHIATRIC DISORDERS | Neuritek Ltd. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-10918640-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10383871-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20170196864-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-9475800-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2016-10-25 | — | — | US | disclosed |
| EP-2265578-B1 | AZETIDINE DERIVATIVES | VERNALIS R&D LTD (GB) | 2015-09-16 | — | — | EP | disclosed |
| US-20150183769-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-9006269-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20130331371-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2013-12-12 | — | — | US | disclosed |
| US-8450346-B2 | Azetidine derivatives as FAAH inhibitors | VERNALIS (R&D) LTD. (GB) | 2013-05-28 | — | — | US | disclosed |
| EP-2265578-A1 | AZETIDINE DERIVATIVES | Vernalis (R&D) Ltd. (GB) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009109743-A1 | AZETIDINE DERIVATIVES | VERNALIS (R&D) LTD. (GB) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918640-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | NAAA 160/4885MMP3 679/4885SCD 93/4885 |
| US-20130331371-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | NAAA 154/4885MMP3 670/4885SCD 87/4885 |
| US-20150183769-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | NAAA 154/4885MMP3 670/4885SCD 87/4885 |
| US-20170196864-A1 | Azetidine Derivatives | FAAH2, FAAH, APEH | NAAA 160/4885MMP3 679/4885SCD 93/4885 |
| US-10383871-B2 | Azetidine derivatives | FAAH2, FAAH, APEH | NAAA 160/4885MMP3 679/4885SCD 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.